ROCKVILLE, Md.--(BUSINESS WIRE)--BioReliance announced today the successful completion of the first commercial application of its proprietary hybrid mycoplasma (HyMy™) assay, combining the efficacy of the broth amplification method of mycoplasma detection and the speed of qPCR detection to cut the turnaround time by more than half on this vital, but lengthy assay.
